Travere stockholders approve 2.7M share increase to 2018 equity incentive plan

Travere Therapeutics, Inc.

Stockholders approved amendment increasing authorized shares under 2018 Equity Incentive Plan by 2,700,000 shares.
Ten directors elected; John Orwin received 50.65M for vs 10.99M withheld.
Advisory vote on named executive officer compensation passed with 56.25M for, 5.36M against.
Ernst & Young ratified as independent auditor for FY2023 with 63.81M for, 30K against.
Plan document filed as Exhibit 99.1.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Travere Therapeutics, Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-17 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-17

Exact text from the filing

Proposal 4: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Travere Therapeutics, Inc. shareholders approved Election of ten directors at the 2023-05-17 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-17

Exact text from the filing

Proposal 1: Election of Directors The Company’s stockholders elected the ten persons listed below to serve until the Company’s 2023 Annual Meeting of Stockholders.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Travere Therapeutics, Inc. shareholders approved Approval of the Company's 2018 Equity Incentive Plan, as amended at the 2023-05-17 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-05-17

Exact text from the filing

Proposal 2: Approval of the Company’s 2018 Equity Incentive Plan, as amended The Company’s stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 2,700,000.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Travere Therapeutics, Inc. shareholders approved Advisory approval of the compensation of named executive officers at the 2023-05-17 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-05-17

Exact text from the filing

Proposal 3: Approval, on an advisory basis, of the compensation of the Company’s named executive officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.

View on SEC.gov

637 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-23-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.